The management of benign and malignant pheochromocytoma and abdominal paraganglioma
| Autor: | B Hamberger, A.-L Hjelm Skog, Anders Höög, Elisabeth Elder |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Vincristine Adolescent endocrine system diseases Cyclophosphamide Dacarbazine Adrenal Gland Neoplasms Pheochromocytoma Metastasis Paraganglioma Internal medicine medicine Humans Aged Retrospective Studies business.industry Retrospective cohort study Combination chemotherapy General Medicine Middle Aged medicine.disease Combined Modality Therapy Treatment Outcome Abdominal Neoplasms Female Surgery Radiology business medicine.drug |
| Zdroj: | European Journal of Surgical Oncology (EJSO). 29:278-283 |
| ISSN: | 0748-7983 |
| DOI: | 10.1053/ejso.2002.1413 |
| Popis: | Aims: To report treatment and outcome in patients with malignant and benign pheochromocytoma and abdominal paraganglioma. Methods: Review of clinical and therapeutic features in 85 patients with pheochromocytoma or abdominal paraganglioma between 1976 and 1999. Results: Thirty-nine of 85 patients presented with symptoms other than classical paroxysmal attacks. Paragangliomas were more often malignant (7/15) than pheochromocytomas (7/70). No recurrences have occurred in 71 patients with tumours initially classified as benign after a median follow-up time of 144 months (range 7–287). Nine of 14 patients with tumours classified as malignant have developed metastasis and/or local recurrence. Treatment of malignant tumours with cyclophosphamide, vincristine and dacarbazine (CVD) improved or stabilised the disease in three of four patients. Conclusion: Life long follow-up of patients with benign pheochromocytoma is not necessary. Combination chemotherapy (CVD) is a valid option in the treatment of malignant pheochromocytomas and abdominal paragangliomas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect